HT2 Evaluation of Tucatinib for HER2-Positive Breast Cancer Patients with Brain Metastases: A United States-Based Cost-Effectiveness Analysis

To evaluate the cost-effectiveness of tucatinib in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) patients with brain metastases (BMs) and the subgroup of active BMs from the United States (US) payer perspective.

Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: L. Dong, D. Nian, Y. Huang, S. Lin, L. Zhong, X. Xu Source Type: research